Fineline Cube

Follow:
14422 Articles
ImmuneOnco Biopharmaceuticals Initiates Phase Ib Study for Amulirafusp Alfa in NMOSD
CompanyDrug

ImmuneOnco Biopharmaceuticals Initiates Phase Ib Study for Amulirafusp Alfa in NMOSD

Henlius Biotech Joins Biosimilars Forum to Expand Global Biosimilars Access
Company

Henlius Biotech Joins Biosimilars Forum to Expand Global Biosimilars Access

MicroPort CardioFlow Medtech's VitaFlow Liberty Flex Receives NMPA Approval
CompanyMedical Device

MicroPort CardioFlow Medtech’s VitaFlow Liberty Flex Receives NMPA Approval

Lepu Scientech's ScienCcrown TAVR System Earns NMPA Medical Device License
CompanyMedical Device

Lepu Scientech’s ScienCcrown TAVR System Earns NMPA Medical Device License

Eli Lilly's Kisunla Receives NMPA Approval for Early Alzheimer's Disease Treatment
CompanyDrug

Eli Lilly’s Kisunla Receives NMPA Approval for Early Alzheimer’s Disease Treatment

BioNova Pharmaceuticals' BN104 Receives Breakthrough Therapy Designation in China
CompanyDrug

BioNova Pharmaceuticals’ BN104 Receives Breakthrough Therapy Designation in China

Sinovent Inc. Submits Pre-NDA for Funobactam, Imipenem, and Cilastatin to NMPA
CompanyDrug

Evopoint Biosciences Submits Pre-NDA for Funobactam, Imipenem, and Cilastatin to NMPA

Xtalpi Inc. Partners with Gnosis Neurodynamics to Develop Neural Drug Screening Platform
CompanyDeals

Xtalpi Inc. Partners with Gnosis Neurodynamics to Develop Neural Drug Screening Platform

GSK's Blenrep and Star Pharma's Topiramate Solution Target Priority Review in China
CompanyDrug

GSK’s Blenrep and Star Pharma’s Topiramate Solution Target Priority Review in China

Sciwind Biosciences' Ecnoglutide Accepted for Review by NMPA for Weight Management
CompanyDrug

Sciwind Biosciences’ Ecnoglutide Accepted for Review by NMPA for Weight Management

Blackstone and Bain Capital Submit Final Bids for Mitsubishi Tanabe Pharma
CompanyDeals

Blackstone and Bain Capital Submit Final Bids for Mitsubishi Tanabe Pharma

Everest Medicines' Velsipity NDA for Ulcerative Colitis Accepted by China's NMPA
CompanyDrug

Everest Medicines’ Velsipity NDA for Ulcerative Colitis Accepted by China’s NMPA